Tekmira Pharmaceuticals Corp. has entered into a multi-year target validation agreement with Bristol-Myers Squibb. BMS will use small interfering RNA (siRNA) molecules formulated by Tekmira in stable nucleic acid-lipid particles (SNALP) to silence target genes of interest. BMS will conduct the preclinical work to validate the function of certain genes and Tekmira will then develop RNAi therapeutic drugs against the therapeutic targets of interest. Tekmira will receive $3 million at the signing o...